Sensus Healthcare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Sensus Healthcare şirketinin toplam hissedar öz sermayesi $52.9M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $58.2M ve $5.3M dir. Sensus Healthcare 'in FAVÖK'ü $8.6M faiz karşılama oranı -9.2 dur. Şirketin $19.0M tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	-9.2x
Nakit	US$18.97m
Eşitlik	US$52.90m
Toplam yükümlülükler	US$5.26m
Toplam varlıklar	US$58.16m

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 5TX 'nin kısa vadeli varlıkları ( $54.5M ) kısa vadeli yükümlülüklerini ( $4.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: 5TX şirketinin kısa vadeli varlıkları ( $54.5M ) uzun vadeli yükümlülüklerini ( $580.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 5TX borçsuzdur.

Borcun Azaltılması: 5TX un 5 yıl önce borcu yoktu.

Borç Kapsamı: 5TX un borcu yoktur, dolayısıyla işletme nakit akışı tarafından karşılanmasına gerek yoktur.

Faiz Kapsamı: 5TX şirketinin borcu bulunmadığından faiz ödemelerinin karşılanması söz konusu değildir.

Sensus Healthcare Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Investor sentiment deteriorates as stock falls 15%

Second quarter 2024 earnings released: EPS: US$0.099 (vs US$0.023 loss in 2Q 2023)

Investor sentiment improves as stock rises 15%

Independent Director recently sold €114k worth of stock

Investor sentiment improves as stock rises 38%

First quarter 2024 earnings released: EPS: US$0.14 (vs US$0.12 loss in 1Q 2023)

Sensus Healthcare, Inc., Annual General Meeting, May 31, 2024

Full year 2023 earnings released: EPS: US$0.03 (vs US$1.47 in FY 2022)

Full year 2023 earnings released: EPS: US$0.03 (vs US$1.47 in FY 2022)

Sensus Healthcare Announces Directors Changes

New major risk - Share price stability

Sensus Healthcare, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Sensus Healthcare, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Sensus Healthcare, Inc. Appoints Michael Sardano as A Director, Effective February 1, 2024

Third quarter 2023 earnings released: US$0.089 loss per share (vs US$0.11 profit in 3Q 2022)

Sensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego

New major risk - Earnings quality

Investor sentiment improves as stock rises 36%

Sensus Healthcare, Inc. (NasdaqCM:SRTS) announces an Equity Buyback for $3 million worth of its shares.

Second quarter 2023 earnings released: US$0.023 loss per share (vs US$0.21 profit in 2Q 2022)

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 15%

Independent Director recently bought €55k worth of stock

Investor sentiment deteriorates as stock falls 36%

First quarter 2023 earnings released: US$0.12 loss per share (vs US$0.97 profit in 1Q 2022)

Full year 2022 earnings released: EPS: US$1.47 (vs US$0.25 in FY 2021)

Investor sentiment deteriorates as stock falls 16%

Now 21% undervalued

Investor sentiment deteriorates as stock falls 18%

Full year 2022 earnings released: EPS: US$1.47 (vs US$0.25 in FY 2021)

Sensus Healthcare, Inc. Announces Senior Management Appointments and Promotions

Investor sentiment improved over the past week

Sensus Healthcare, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Sensus Healthcare, Inc. to Report Q4, 2022 Results on Feb 09, 2023

Insufficient new directors

Third quarter 2022 earnings released: EPS: US$0.11 (vs US$0.012 in 3Q 2021)

Investor sentiment deteriorated over the past week

Sensus Healthcare, Inc. Introduces Silk(TM) Laser Hair Removal System

Co-Founder recently sold €524k worth of stock

Sensus Healthcare, Inc. Appoints Mohammad K. Khan to Medical Advisory Board

Investor sentiment improved over the past week

Independent Director recently sold €686k worth of stock

Sensus Healthcare, Inc. Launches Upgrade to its SRT-100 Vision System with New Ultrasound Capabilities

Second quarter 2022 earnings released: EPS: US$0.21 (vs US$0.017 loss in 2Q 2021)

Investor sentiment improved over the past week

Independent Director recently sold €72k worth of stock

First quarter 2022 earnings released: EPS: US$0.97 (vs US$0.068 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings released: EPS: US$0.25 (vs US$0.42 loss in FY 2020)

Investor sentiment improved over the past week

Co-Founder recently sold €1.2m worth of stock

Empyrean Medical System Inc. acquired Sculptura Assets of Sensus Healthcare, Inc. for $15 million.

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Sensus Healthcare, Inc. Announces Three Promotions

Sensus Healthcare, Inc. Announces Executive Changes

Now 20% undervalued

Sensus Healthcare, Inc. Provides Earnings Guidance for the Fourth Quarter of 2021

Forecast breakeven date moved forward to 2021

Sensus Healthcare, Inc. Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia

Third quarter 2021 earnings released: EPS US$0.012 (vs US$0.10 loss in 3Q 2020)

Forecast to breakeven in 2022

Second quarter 2021 earnings released: US$0.017 loss per share (vs US$0.16 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.068 loss per share (vs US$0.22 loss in 1Q 2020)

Colorado State University, Flint Animal Cancer Center Applies Sensus Healthcare’s SRT Non-Surgical Treatment to Animal Care

Full year 2020 earnings released: US$0.42 loss per share (vs US$0.10 loss in FY 2019)

Revenue beats expectations

New 90-day high: €3.55

New 90-day high: €3.53

New 90-day high: €3.02

Sensus Healthcare, Inc. Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100™ Systems

Sensus Healthcare, Inc. Announces Study Showing Single Low Dose of Superficial Radiation Therapy Prevents Keloid Recurrence Following Surgical Excision

Third quarter 2020 earnings released: US$0.10 loss per share

Revenue misses expectations

Revenue misses expectations